MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Perrigo Company plc Interest Expense 2011-2026 | PRGO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Perrigo Company plc
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -13.2 M | 900 K | 10.4 M | -53.1 M | -26.7 M | -16.3 M | 68.9 M | -6.1 M | 10.1 M | -22.7 M | -334 M | -25.1 M | -900 K | 3.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 68.9 M | -334 M | -28.9 M |
Quarterly Interest Expense Perrigo Company plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.6 M | -2.6 M | 400 K | - | 4.1 M | -3.4 M | -400 K | - | 600 K | 9.7 M | -500 K | - | 4 M | -53.8 M | 1.1 M | - | -18.5 M | 400 K | -2.4 M | - | 1 M | -17.1 M | -1.7 M | - | 71 M | -2.3 M | -3.2 M | - | -200 K | -7.9 M | -4.3 M | - | 3.6 M | -6.1 M | 3.5 M | - | -1 M | -28.8 M | -2.5 M | - | -10.9 M | -15.8 M | -13 M | -59.3 M | -2.7 M | -61.9 M | -2.7 M | -4.1 M | -1 M | -4.1 M | -800 K | -100 K | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 71 M | -61.9 M | -5.79 M |
Interest Expense of other stocks in the Drug manufacturers industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aerie Pharmaceuticals
AERI
|
-27.9 M | - | - | $ 754 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
1.12 M | - | 7.5 % | $ 6.35 M | USA |
 |
Catalent
CTLT
|
-4 M | - | - | $ 11.5 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.92 K | - | 0.86 % | $ 117 M | USA |
 |
DURECT Corporation
DRRX
|
2.24 M | - | - | $ 50.1 M | USA |
 |
Canopy Growth Corporation
CGC
|
74.6 M | $ 1.11 | 4.27 % | $ 119 M |  Canada |
 |
Endo International plc
ENDP
|
350 M | - | - | $ 28.9 M |  Irlanda |
 |
Agile Therapeutics
AGRX
|
1.42 M | - | 10.11 % | $ 58.2 M | USA |
 |
Evoke Pharma
EVOK
|
500 K | - | - | $ 36.6 M | USA |
 |
Alimera Sciences
ALIM
|
10.2 M | - | - | $ 142 M | USA |
 |
Evolus
EOLS
|
-539 K | $ 5.19 | 25.54 % | $ 335 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
13 M | - | - | $ 2.06 B |  France |
 |
Jupiter Wellness
JUPW
|
-5.37 M | - | - | $ 33.6 M | USA |
 |
China Pharma Holdings
CPHI
|
27.4 K | $ 0.58 | 2.89 % | $ 10.1 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
606 K | $ 4.18 | -8.73 % | $ 58.8 M | USA |
 |
HEXO Corp.
HEXO
|
20.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Harrow Health
HROW
|
47 K | $ 39.81 | 3.11 % | $ 1.46 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
12 K | - | - | $ 193 M | Canada |
 |
Athenex
ATNX
|
25.8 M | - | -23.39 % | $ 1.76 M | USA |
 |
Emergent BioSolutions
EBS
|
87.9 M | $ 8.69 | -2.47 % | $ 445 M | USA |
 |
ProPhase Labs
PRPH
|
764 K | - | - | $ 5.07 M | USA |
 |
Assertio Holdings
ASRT
|
2.78 M | $ 12.24 | 2.9 % | $ 869 M | USA |
 |
Radius Health
RDUS
|
18.3 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
-28 M | $ 5.63 | -1.66 % | $ 2.05 B | Canada |
 |
Lannett Company
LCI
|
58 M | - | 1.15 % | $ 7.11 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
4.04 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
20 K | $ 2.96 | 3.1 % | $ 390 M | USA |
 |
Rockwell Medical
RMTI
|
2.3 M | $ 0.9 | 0.08 % | $ 21 M | USA |
 |
Sundial Growers
SNDL
|
81 K | $ 1.55 | 1.31 % | $ 3.37 M | Canada |
 |
TherapeuticsMD
TXMD
|
300 K | $ 2.24 | 0.94 % | $ 23.4 M | USA |
 |
Veru
VERU
|
862 K | $ 2.67 | 5.95 % | $ 360 M | USA |
 |
Viatris
VTRS
|
573 M | $ 14.7 | -1.31 % | $ 17.6 B | USA |
 |
Pacira BioSciences
PCRX
|
-373 K | $ 22.6 | 2.26 % | $ 1.05 B | USA |
 |
PetIQ
PETQ
|
38.3 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
19.5 M | - | - | $ 1.08 B | USA |
 |
Recro Pharma
REPH
|
9.96 M | - | -4.76 % | $ 65.3 M | USA |
 |
Relmada Therapeutics
RLMD
|
5.15 M | $ 4.77 | 2.14 % | $ 144 M | USA |
 |
cbdMD
YCBD
|
-29.5 K | $ 0.8 | 3.77 % | $ 3.45 M | USA |
 |
SCYNEXIS
SCYX
|
3.13 M | $ 0.77 | 2.75 % | $ 36.8 M | USA |
 |
Solid Biosciences
SLDB
|
652 K | $ 6.15 | 3.19 % | $ 251 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-10 K | $ 2.69 | -2.18 % | $ 3.34 M | USA |
 |
Tricida
TCDA
|
17.6 M | - | - | $ 3.25 M | USA |
 |
Tilray
TLRY
|
46.6 M | $ 7.51 | 2.04 % | $ 4.64 B | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
80.2 K | - | - | $ 55.5 M | USA |